Henan Lingrui Pharmaceutical Co., Ltd. Stock price

Equities

600285

CNE000001501

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-02-22 pm EST 5-day change 1st Jan Change
19 CNY -1.04% Intraday chart for Henan Lingrui Pharmaceutical Co., Ltd. -0.37% +11.05%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * 3.46B 480M Sales 2024 * 3.96B 551M Capitalization 10.71B 1.49B
Net income 2023 * 537M 74.62M Net income 2024 * 641M 89.07M EV / Sales 2023 * 3.1 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 2.7 x
P/E ratio 2023 *
20 x
P/E ratio 2024 *
16.8 x
Employees 2,524
Yield 2023 *
3.89%
Yield 2024 *
4.63%
Free-Float 75.18%
More Fundamentals * Assessed data
Dynamic Chart
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback announced on February 1, 2022 has expired with 19,086,325 shares, representing 3.39% for CNY 184.47 million. CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021. CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021. CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021. CI
Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news
1 day-1.04%
1 week-0.37%
Current month+12.23%
1 month+11.18%
3 months+11.50%
6 months+20.33%
Current year+11.05%
More quotes
1 week
18.67
Extreme 18.67
19.76
1 month
16.35
Extreme 16.35
19.85
Current year
16.15
Extreme 16.15
19.85
1 year
14.30
Extreme 14.3
19.85
3 years
8.24
Extreme 8.24
19.85
5 years
7.66
Extreme 7.66
19.85
10 years
5.81
Extreme 5.8133
19.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 40 -
Director of Finance/CFO 55 -
Director/Board Member 51 -
Members of the board TitleAgeSince
Chief Executive Officer 40 -
Director/Board Member 60 06-04-17
Director/Board Member 55 23-05-17
More insiders
Date Price Change Volume
24-02-23 19 -1.04% 6,908,723
24-02-22 19.2 +0.16% 6,849,490
24-02-21 19.17 -2.79% 10,513,120
24-02-20 19.72 +4.73% 11,602,870

End-of-day quote Shanghai S.E., February 22, 2024

More quotes
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19
Average target price
-
Spread / Average Target
-100.00%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Henan Lingrui Pharmaceutical Co., Ltd. - Shanghai S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW